Moderna (MRNA) Receivables - Other (2017 - 2026)

Moderna (MRNA) has 10 years of Receivables - Other data on file, last reported at $39.0 million in Q1 2026.

• Receivables - Other for Q1 2026 came in at $39.0 million, up 21.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.0 million (up 21.88% YoY), and the FY2025 annual result was $42.0 million, down 28.81% from the prior year.
• Receivables - Other slipped to $39.0 million in Q1 2026 per MRNA's latest filing, from $42.0 million in the prior quarter.
• Over five years, Receivables - Other peaked at $62.0 million in Q1 2024 and troughed at $32.0 million in Q1 2025.
• A 5-year average of $48.5 million and a median of $50.5 million in 2022 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2022 and 2025: Receivables - Other jumped 750.0% in 2022, then sank 48.39% in 2025.
• A 5-year view of Receivables - Other shows it stood at $42.0 million in 2022, then jumped by 40.48% to $59.0 million in 2023, then changed by 0.0% to $59.0 million in 2024, then declined by 28.81% to $42.0 million in 2025, then fell by 7.14% to $39.0 million in 2026.
• Business Quant data shows MRNA's Receivables - Other at $39.0 million in Q1 2026, $42.0 million in Q4 2025, and $61.0 million in Q2 2025.